Stress, menopause and vulnerability for psychiatric illness

Click to increase image sizeClick to decrease image size

Financial disclosure

In the past 3 years, Dr Nemeroff consulted to, served on the speakers’ bureau and/or board of directors, has been a grant recipient and/or owned equity in one or more of the following: Abbott Laboratories, Acadia Pharmaceuticals, American Foundation for Suicide Prevention (AFSP), American Psychiatric Institute for Research and Educations (APIRE), AstraZeneca, BMC-JR LLC, Bristol-Myers-Squibb, CeNeRx, Corcept, Cypress Biosciences, Cyberonics, Eli Lilly, Entrepreneur’s Fund, Forest Laboratories, George West Mental Health Foundation, GlaxoSmithKline, i3 DLN, Janssen Pharmaceutica, Lundbeck, National Alliance for Research on Schizophrenia and Depression (NARSAD), Neuronetics, NIMH, NFMH, NovaDel Pharma, Otsuka, Pfizer Pharmaceuticals, Quintiles, Reevax, UCB Pharma, Wyeth-Ayerst.

Currently, Dr Nemeroff serves on the scientific advisory board for Astra-Zeneca, Johnson & Johnson, Pharma Neuroboost, Forest Laboratories, Quintiles and NARSAD. He is a grant recipient from NIH, NARSAD and AFSP. He serves on the Board of Directors of AFSP, APIRE, NovaDel Pharma-ceuticals and the George West Mental Health Foundation. He owns equity in CeNeRx and Reevax. He owns stock or stock options in Corcept, Cypress Biosciences and NovaDel.

The author is supported by NIMH MH-39415, MH-42088, MH-58922, MH-69056 and MH-77083.